Sugi Predict

Sugi Predict / Compounds / SCHEMBL248795

SCHEMBL248795

SCHEMBL248795

Cc1cc(F)cc(B(O)O)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 1/20 0.42
▸ LPL P06858 1/20 0.42
▸ LIPG Q9Y5X9 1/20 0.42
▸ ACHE P22303 3/20 0.41
▸ RAPGEF4 Q8WZA2 2/20 0.33
▸ HDAC3 O15379 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ ORAI1 Q96D31 2/20 0.32
▸ ORAI2 Q96SN7 2/20 0.32
▸ ORAI3 Q9BRQ5 2/20 0.32
▸ TRPV6 Q9H1D0 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ CA12 O43570 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2558951 0.85 CA2 (0.33) CA2LPLLIPGACHE
SCHEMBL124847 0.82 CA1 (0.45) CA2LPLLIPGORAI1ORAI2
SCHEMBL7657848 0.82 CA2 (0.52) CA2LPLLIPGACHEORAI1
SCHEMBL364635 0.82 CA2 (0.52) CA2LPLLIPGACHEORAI1
Ammonia Solution, Strong SCHEMBL28219615 0.79 LPL (0.50) CA2LPLLIPGACHEORAI1
SCHEMBL8509685 0.79 LPL (0.50) CA2LPLLIPGACHEORAI1
SCHEMBL29249836 0.74 CA12 (0.35) CA2LPLLIPGORAI1ORAI2
SCHEMBL15270190 0.73 ALDH1A1 (0.57) CA2LPLLIPGACHEORAI1
SCHEMBL675958 0.73 CA12 (0.57) ORAI1ORAI2ORAI3TRPV6CA12
SCHEMBL15976048 0.73 ACHE (0.33) ACHERAPGEF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 — — EP disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 — — US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 — — EP disclosed
US-20260008767-A1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2026-01-08 — — US disclosed
US-20250376385-A1 PEROVSKITE POWDER, LIGHT EMITTING LAYER FOR LIGHT EMITTING DEVICE AND METHOD FOR MANUFACTURING THE SAME SEOUL NAT UNIV R&DB FOUNDATION (KR) 2025-12-11 — — US disclosed
US-20250376621-A1 HALIDE PEROVSKITE NANOCRYSTAL PARTICLES, EMITTERS, MANUFACTURING METHOD THEREOF SEOUL NAT UNIV R&DB FOUNDATION (KR) 2025-12-11 — — US disclosed
EP-4634202-A1 SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2025-10-22 — — EP disclosed
EP-4619386-A1 ARYL THIOETHERS AS HIF-2ALPHA INHIBITORS F. Hoffmann-La Roche AG (CH) 2025-09-24 — — EP disclosed
EP-4608808-A1 SOMATOSTATIN RECEPTOR 2 AGONISTS AND USES THEREOF Basecamp Bio Inc. (KY) 2025-09-03 — — EP disclosed
EP-4548974-A2 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2025-05-07 — — EP disclosed
US-7947663-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2011-05-24 — — US disclosed
EP-2313407-A1 cMET INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2011-04-27 — — EP disclosed
WO-2010068242-A1 PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2010-06-17 — — WO disclosed
US-20100063054-A1 cMET INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-11 — — US disclosed
WO-2010019899-A1 cMET INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 — — WO disclosed
US-20090099131-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY DISCOVERY, INC. (US) 2009-04-16 — — US disclosed
EP-2027230-A1 RED EMITTER COMPLEXES OF IR(III) AND DEVICES MADE WITH SUCH COMPOUNDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2009-02-25 — — EP disclosed
WO-2008063300-A2 BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2008-05-29 — — WO disclosed
WO-2007143201-A1 RED EMITTER COMPLEXES OF IR(III) AND DEVICES MADE WITH SUCH COMPOUNDS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-12-13 — — WO disclosed
US-20070278936-A1 Red emitter complexes of IR(III) and devices made with such compounds E. I. DU PONT DE NEMOURS AND COMPANY 2007-12-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063054-A1 cMET INHIBITORS CEPT1, LCAT, GNMT CA2 1988/4885LPL 1677/4885LIPG 429/4885
US-20070278936-A1 Red emitter complexes of IR(III) and devices made with such compounds IK, TBL3, RTN3 CA2 3829/4885LPL 4263/4885LIPG 4694/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH CA2 2217/4885LPL 2/4885LIPG 17/4885
US-20090099131-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 CA2 1331/4885LPL 180/4885LIPG 272/4885
US-20260008767-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR3, SSTR2 CA2 127/4885LPL 1372/4885LIPG 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.